Leonard Minuk

1.7k total citations
31 papers, 522 citations indexed

About

Leonard Minuk is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Leonard Minuk has authored 31 papers receiving a total of 522 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 9 papers in Pathology and Forensic Medicine and 9 papers in Oncology. Recurrent topics in Leonard Minuk's work include Lymphoma Diagnosis and Treatment (9 papers), Hemophilia Treatment and Research (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Leonard Minuk is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Hemophilia Treatment and Research (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Leonard Minuk collaborates with scholars based in Canada, United States and Germany. Leonard Minuk's co-authors include Amy Kimball, Vânia Hungria, Anita Zahlten‐Kumeli, Hartmut Goldschmidt, Robert Z. Orlowski, Rubén Niesvizky, Thierry Façon, Meletios Α. Dimopoulos, Douglas Joshua and Heinz Ludwig and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Hepatology.

In The Last Decade

Leonard Minuk

29 papers receiving 515 citations

Peers

Leonard Minuk

HEMAT

ONCOL

GENET

PFM

Jean Pierre Marie France

Guillemette Fouquet France

Anıl Aktaş Samur United States

Ligen Liu China

M Teramura Japan

Sophie Huybrechts Belgium

Sara Santos Franco United Kingdom

Xinping Zhou China

Margarita Blanes Spain

M Pearce United States

Jean Pierre Marie France

Leonard Minuk

186 ×0.5

HEMAT

130 ×0.5

113 ×0.7

ONCOL

56 ×0.7

GENET

20 ×0.5

PFM

Citations per year, relative to Leonard Minuk Leonard Minuk (= 1×) peers Jean Pierre Marie

Countries citing papers authored by Leonard Minuk

Since Specialization

Citations

This map shows the geographic impact of Leonard Minuk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leonard Minuk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leonard Minuk more than expected).

Fields of papers citing papers by Leonard Minuk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leonard Minuk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leonard Minuk. The network helps show where Leonard Minuk may publish in the future.

Co-authorship network of co-authors of Leonard Minuk

This figure shows the co-authorship network connecting the top 25 collaborators of Leonard Minuk. A scholar is included among the top collaborators of Leonard Minuk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leonard Minuk. Leonard Minuk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotb, Rami, et al.. (2025). Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(7). e510–e512.

Timmerman, John M., David Lavie, Gareth P. Gregory, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7055–7055. 2 indexed citations

Johnson, Nathalie A., David Lavie, Peter Borchmann, et al.. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. Blood. 142(Supplement 1). 1693–1693. 3 indexed citations

Santoro, Armando, Nathalie A. Johnson, Kerry J. Savage, et al.. (2023). Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study. Blood. 142(Supplement 1). 1725–1725. 1 indexed citations

Dao, Vi, et al.. (2020). A multicenter review of infusion-related reactions to daratumumab for relapsed multiple myeloma in the real world setting. Journal of Oncology Pharmacy Practice. 27(4). 907–910. 3 indexed citations

Ludwig, Heinz, Andrew Spencer, Tibor Kovacsovics, et al.. (2017). Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study. Blood. 130. 3125–3125. 4 indexed citations

Dimopoulos, Meletios Α., Hartmut Goldschmidt, Rubén Niesvizky, et al.. (2017). Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. The Lancet Oncology. 18(10). 1327–1337. 281 indexed citations

Lazo‐Langner, Alejandro, et al.. (2016). Effect of unintentional cyclophosphamide underdosing on diffuse large B-cell lymphoma response to chemotherapy: a retrospective review. CMAJ Open. 4(2). E236–E239. 2 indexed citations

Louzada, Martha, Cyrus C. Hsia, Fatimah Al‐Ani, et al.. (2016). Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study. PubMed. 16(1). 7–7. 7 indexed citations

10.

Jackson, Shannon, Leonard Minuk, Michelle Sholzberg, et al.. (2015). Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. PubMed. 15(1). 4–4. 22 indexed citations

11.

Minuk, Leonard, Shannon Jackson, Alfonso Iorio, et al.. (2015). Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia. 21(6). 736–741. 25 indexed citations

12.

Mangel, Joy, et al.. (2014). Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A. Blood Coagulation & Fibrinolysis. 25(8). 820–823. 19 indexed citations

13.

Minuk, Leonard, et al.. (2014). Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia. 21(3). e156–e166. 18 indexed citations

14.

Minuk, Leonard, Ian Chin‐Yee, Alejandro Lazo‐Langner, et al.. (2011). Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study. Leukemia & lymphoma. 53(1). 57–63. 21 indexed citations

15.

Mahony, James B., et al.. (2011). The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies. Leukemia & lymphoma. 52(9). 1736–1741. 11 indexed citations

16.

Minuk, Leonard, et al.. (2011). The Prevalence of Cardiovascular Risk Factors in Individuals with Hemophilia. Blood. 118(21). 4319–4319. 1 indexed citations

17.

Minuk, Leonard, et al.. (2010). Access to Thalidomide for the Treatment of Multiple Myeloma in Canada: Physician Behaviours and Ethical Implications. Current Oncology. 17(4). 11–19. 4 indexed citations

18.

Minuk, Leonard, et al.. (2010). Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated. Thrombosis Journal. 8(1). 10–10. 12 indexed citations

19.

Minuk, Gerald Y., Kim Hawkins, Kelly Kaita, et al.. (2010). Daily Ciprofloxacin Treatment for Patients with Advanced Liver Disease Awaiting Liver Transplantation Reduces Hospitalizations. Digestive Diseases and Sciences. 56(4). 1235–1241. 1 indexed citations

20.

Minuk, Gerald Y., Manna Zhang, Yuewen Gong, et al.. (2007). Decreased hepatocyte membrane potential differences and GABAa-β3 expression in human hepatocellular carcinoma. Hepatology. 45(3). 735–745. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact